Cargando…

Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown

AIMS: Billions of people have been under lockdown in an attempt to prevent COVID-19 spread. Lifestyle changes during lockdown could lead to deterioration of glycemic control in type 1 diabetes (T1D). We aimed to assess the impact of COVID-19 lockdown on the glycemic control of pediatric patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Brener, Avivit, Mazor-Aronovitch, Kineret, Rachmiel, Marianna, Levek, Noa, Barash, Galia, Pinhas-Hamiel, Orit, Lebenthal, Yael, Landau, Zohar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538839/
https://www.ncbi.nlm.nih.gov/pubmed/33026497
http://dx.doi.org/10.1007/s00592-020-01596-4
_version_ 1783590940339863552
author Brener, Avivit
Mazor-Aronovitch, Kineret
Rachmiel, Marianna
Levek, Noa
Barash, Galia
Pinhas-Hamiel, Orit
Lebenthal, Yael
Landau, Zohar
author_facet Brener, Avivit
Mazor-Aronovitch, Kineret
Rachmiel, Marianna
Levek, Noa
Barash, Galia
Pinhas-Hamiel, Orit
Lebenthal, Yael
Landau, Zohar
author_sort Brener, Avivit
collection PubMed
description AIMS: Billions of people have been under lockdown in an attempt to prevent COVID-19 spread. Lifestyle changes during lockdown could lead to deterioration of glycemic control in type 1 diabetes (T1D). We aimed to assess the impact of COVID-19 lockdown on the glycemic control of pediatric patients with T1D. METHODS: This observational real-life study from the AWeSoMe Group assessed continuous glucose monitoring (CGM) metrics of 102 T1D patients (52.9% males, mean age 11.2 ± 3.8 years, mean diabetes duration 4.2 ± 3.8 years) who used  Dexcom G5. The data were accessed without any interface between patients, caregivers, and the diabetes team. Study variables from CGM metrics were: mean glucose level, time-in-range (TIR, 70–180 mg/dL; 3.9–10 mmol/L), hypoglycemia (< 54 mg/dL; < 3 mmol/L), hyperglycemia (> 250 mg/dL; > 13.3 mmol/L), coefficient of variation (CV), and time CGM active before and during lockdown. Delta-variable = lockdown variable minus before-lockdown variable. RESULTS: The mean TIR was 60.9 ± 14.3% before lockdown, with no significant change during lockdown (delta-TIR was 0.9 ± 7.9%). TIR during lockdown was significantly correlated with TIR before lockdown (r = 0.855, P < 0.001). Patients with improved TIR (delta-TIR > 3%) were significantly older than patients with stable or worse TIR (P = 0.028). Children aged < 10 years had a significantly higher CV before lockdown and during lockdown than children aged ≥ 10 years (P = 0.02 and P = 0.005, respectively). Among children aged < 10 years, a multiple linear regression model revealed associations of age and lower socioeconomic cluster with delta-TIR (F = 4.416, P = 0.019) and with delta-mean glucose (F = 4.459, P = 0.018). CONCLUSIONS: CGM metrics in pediatric patients with T1D were relatively stable during a nationwide lockdown. Intervention plans should focus on younger patients with lower socioeconomic position.
format Online
Article
Text
id pubmed-7538839
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-75388392020-10-07 Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown Brener, Avivit Mazor-Aronovitch, Kineret Rachmiel, Marianna Levek, Noa Barash, Galia Pinhas-Hamiel, Orit Lebenthal, Yael Landau, Zohar Acta Diabetol Original Article AIMS: Billions of people have been under lockdown in an attempt to prevent COVID-19 spread. Lifestyle changes during lockdown could lead to deterioration of glycemic control in type 1 diabetes (T1D). We aimed to assess the impact of COVID-19 lockdown on the glycemic control of pediatric patients with T1D. METHODS: This observational real-life study from the AWeSoMe Group assessed continuous glucose monitoring (CGM) metrics of 102 T1D patients (52.9% males, mean age 11.2 ± 3.8 years, mean diabetes duration 4.2 ± 3.8 years) who used  Dexcom G5. The data were accessed without any interface between patients, caregivers, and the diabetes team. Study variables from CGM metrics were: mean glucose level, time-in-range (TIR, 70–180 mg/dL; 3.9–10 mmol/L), hypoglycemia (< 54 mg/dL; < 3 mmol/L), hyperglycemia (> 250 mg/dL; > 13.3 mmol/L), coefficient of variation (CV), and time CGM active before and during lockdown. Delta-variable = lockdown variable minus before-lockdown variable. RESULTS: The mean TIR was 60.9 ± 14.3% before lockdown, with no significant change during lockdown (delta-TIR was 0.9 ± 7.9%). TIR during lockdown was significantly correlated with TIR before lockdown (r = 0.855, P < 0.001). Patients with improved TIR (delta-TIR > 3%) were significantly older than patients with stable or worse TIR (P = 0.028). Children aged < 10 years had a significantly higher CV before lockdown and during lockdown than children aged ≥ 10 years (P = 0.02 and P = 0.005, respectively). Among children aged < 10 years, a multiple linear regression model revealed associations of age and lower socioeconomic cluster with delta-TIR (F = 4.416, P = 0.019) and with delta-mean glucose (F = 4.459, P = 0.018). CONCLUSIONS: CGM metrics in pediatric patients with T1D were relatively stable during a nationwide lockdown. Intervention plans should focus on younger patients with lower socioeconomic position. Springer Milan 2020-10-07 2020 /pmc/articles/PMC7538839/ /pubmed/33026497 http://dx.doi.org/10.1007/s00592-020-01596-4 Text en © Springer-Verlag Italia S.r.l., part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Brener, Avivit
Mazor-Aronovitch, Kineret
Rachmiel, Marianna
Levek, Noa
Barash, Galia
Pinhas-Hamiel, Orit
Lebenthal, Yael
Landau, Zohar
Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown
title Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown
title_full Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown
title_fullStr Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown
title_full_unstemmed Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown
title_short Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown
title_sort lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under covid-19 lockdown
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538839/
https://www.ncbi.nlm.nih.gov/pubmed/33026497
http://dx.doi.org/10.1007/s00592-020-01596-4
work_keys_str_mv AT breneravivit lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown
AT mazoraronovitchkineret lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown
AT rachmielmarianna lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown
AT leveknoa lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown
AT barashgalia lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown
AT pinhashamielorit lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown
AT lebenthalyael lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown
AT landauzohar lessonslearnedfromthecontinuousglucosemonitoringmetricsinpediatricpatientswithtype1diabetesundercovid19lockdown